NCT05407779View on ClinicalTrials.gov

Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 22, 2021

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions
Healthy
Interventions
BIOLOGICAL

BCD-180, dose 1

anti-TRBV9 monoclonal antibody single infusion at dose 1

BIOLOGICAL

BCD-180, dose 2

anti-TRBV9 monoclonal antibody, single infusion at dose 2

BIOLOGICAL

BCD-180, dose 3

anti-TRBV9 monoclonal antibody, single infusion at dose 3

BIOLOGICAL

BCD-180, dose 4

anti-TRBV9 monoclonal antibody, single infusion at dose 4

BIOLOGICAL

BCD-180, dose 5

anti-TRBV9 monoclonal antibody, single infusion at dose 5

BIOLOGICAL

BCD-180, dose 6

anti-TRBV9 monoclonal antibody, single infusion at dose 6

BIOLOGICAL

BCD-180, dose 7

anti-TRBV9 monoclonal antibody, single infusion at dose 7

Trial Locations (1)

Unknown

X7 Clinical Research, Saint Petersburg

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY

NCT05407779 - Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers | Biotech Hunter | Biotech Hunter